The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary.

Autor: Kok DL; Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia., Wang A; Peter McCallum Cancer Centre, Melbourne, Victoria, Australia., Xu W; Princess Alexandra Hospital, Brisbane, Queensland, Australia., Chua MST; Peter McCallum Cancer Centre, Melbourne, Victoria, Australia., Guminski A; Royal North Shore Hospital, St. Leonards, New South Wales, Australia., Veness M; Westmead Hospital, University of Sydney, Westmead, New South Wales, Australia., Howle J; Westmead Hospital, Westmead, New South Wales, Australia., Tothill R; University of Melbourne, Melbourne, Victoria, Australia., Kichendasse G; Flinders Medical Centre, Bedford Park, South Australia, Australia., Poulsen M; ROPART South Brisbane, South Brisbane, Queensland, Australia., Sandhu S; Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia., Fogarty G; St Vincent's Hospital, Sydney, New South Wales, Australia.
Jazyk: angličtina
Zdroj: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2020 Dec; Vol. 16 (6), pp. 312-319. Date of Electronic Publication: 2020 Aug 05.
DOI: 10.1111/ajco.13407
Abstrakt: Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine tumor of the skin with an estimated disease-associated mortality of 15-33%. Australia has a higher incidence of MCC compared to the rest of the world, thought to be due to a higher ultraviolet index. The Australian MCC population is distinct from the MCC population of the Northern hemisphere, characterized by a predominantly viral negative etiology with high tumor mutational burden. The optimal management of MCC and the choice of treatment modality vary significantly across the world and even between institutions within Australia. Historically, the treatment for MCC has been resection followed by radiotherapy (RT), though definitive RT is an alternative treatment used commonly in Australia. The arrival of immune checkpoint inhibitors and the mounting evidence that MCC is a highly immunogenic disease is transforming the treatment landscape for MCC. Australia is playing a key role in the further development of treatment options for MCC with two upcoming Australian/New Zealand investigator-initiated clinical trials that will explore the interplay of RT and immunotherapy in the treatment of early and late stage MCC.
(© 2020 The Authors. Asia-Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje